CHMP Adopts Positive Opinion Recommending Change To The Terms Of The Marketing Authorization For The Medicinal Product Abecma, Extension To The Existing Indication To Include Treatment Of Adult Patients With Relapsed And Refractory Multiple Myeloma Who Have Received At Least Two Prior Therapies
Portfolio Pulse from Benzinga Newsdesk
The Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the marketing authorization for Abecma, extending its indication to treat adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies.
January 26, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb, the company behind Abecma, may see a positive impact on its stock as the CHMP's positive opinion could lead to expanded use in the EU and potentially increased sales.
The CHMP's positive opinion is a significant regulatory milestone that can lead to increased market access and sales for Abecma in the European Union. This is likely to be viewed positively by investors and could result in a short-term uptick in BMY's stock price as the market anticipates growth in revenue from the expanded indication.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100